Johnson & Johnson is ready to start trialing its Ebola vaccine in Africa, where Merck and NewLink are preparing to take theirs into Phase III. GlaxoSmithKline is also testing its jab there. But while thousands of healthcare workers have volunteered to participate in Ebola vaccine trials, the decision to mass-vaccinate against the disease is still up in the air.
NewLink's Ebola vaccine tie-up with Merck continues to pay off.
Novavax announced on Thursday that it would take its Ebola candidate to Australia for a Phase I trial involving 230 healthy adults. It is the fourth company to bring an Ebola vaccine to human trials, but Novavax says it has a better vaccine.
The current Ebola outbreak may be starting to wane, but scientists agree they'll need a stockpile of vaccines to tackle the next one. And that means developing next-generation shots that can fight off multiple strains.
GlaxoSmithKline's Ebola candidate will be the first of several experimental vaccines to undergo large-scale clinical trials. On Friday, the company shipped an initial batch of 300 vials of the vaccine, ChAd3, to Liberia, one of the main countries affected by Ebola.
Johnson & Johnson may have been third to bring its Ebola vaccine to human trials, but it is about to pick up the pace on developing its candidate, thanks to a €100 million grant from a European public-private partnership.
GlaxoSmithKline and tandem Merck and NewLink may have only recently ramped up development efforts for their Ebola vaccine candidates, but late-stage trials of the jabs in the affected countries are already on the horizon, the World Health Organization says.
The latest drugmaker diving into the Ebola vaccine race? India's Zydus Cadila.
Johnson & Johnson started Phase I trials Tuesday for its Ebola vaccine, which its Janssen subsidiary developed in collaboration with Denmark's Bavarian Nordic. But does J&J;'s candidate come too late to catch up with its rivals and help combat the current epidemic?
The previously suspended Swiss trial of Merck and NewLink's experimental Ebola vaccine is back on, but this time at a lower dose.